ATP6AP2 and renal cell carcinoma: Treatment with the renin inhibitor aliskiren demonstrated antiproliferative effects of RCC [39]; therefore, it could be hypothesized that the upregulation of PRR could enhance renin activity, contributing to the stimulation of ACE/AngII/AT1R axis in RCC tissues.